Drug Profile
Research programme: fibroblast growth factor agonists - sanofi-aventis
Alternative Names: SAR 106881Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Small molecules
- Mechanism of Action Fibroblast growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Vascular disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Vascular-disorders in Europe (Parenteral)
- 12 Feb 2008 Preclinical trials in Vascular disorders in Europe (unspecified route)